Efforts to Determine the Role of Oxidant Stress in Dialysis Outcomes

Seminars in Dialysis

Volumn 16, Issue 6, 2003, Pages 488-491

  Handelman, Garry J ^a  

^a UNIVERSITY OF MASSACHUSETTS LOWELL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIOXIDANT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCARBON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE; MALONALDEHYDE; PARATHYROID HORMONE;

CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; CRITICAL ILLNESS; DIALYSIS; FOLLOW UP; HEART DISEASE; HUMAN; INFLAMMATION; KIDNEY FAILURE; LONGITUDINAL STUDY; MORBIDITY; MORTALITY; OXIDATIVE STRESS; PREDICTION; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; HUMANS; OXIDATIVE STRESS; PREDICTIVE VALUE OF TESTS; REACTIVE OXYGEN SPECIES; RENAL DIALYSIS;

EID: 0346218054     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139X.2003.16105.x     Document Type: Conference Paper

References (49)

1. Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F: Imbalance of oxidants and antioxidants in haemodialysis patients. Blood Purif 17:99-106, 1999
2. Morena M, Cristol JP, Canaud B: Why hemodialysis patients are in a pro-oxidant state? What could be done to correct the pro/antioxidant imbalance. Blood Purif 18:191-199, 2000
3. Handelman GJ. Evaluation of oxidant stress in dialysis patients. Blood Purif 18:343-349, 2000
4. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P, Levin NW: Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 38:1408-1413, 2001
5. Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
6. Massy Z, Nguyen-Khoa T: Oxidative stress and renal failure: markers and management. J Nephrol 15:336-341, 2002
7. Ward RA, McLeish KR: Oxidant stress in hemodialysis patients: what are the determining factors? Artif Organs 27:230-236, 2003
8. Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW, Blumberg JB: Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 59:1960-1966, 2001
9. Ikizler TA, Morrow JD, Roberts LJ, Evanson JA, Becker B, Hakim RM, Shyr Y, Himmelfarb J: Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58:190-197, 2002
10. Lim PS, Chang YM, Thien LM, Wang NP, Yang CC, Chen TT, Hsu WM: 8-iso-prostaglandin F(2alpha) as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 20:537-542, 2002
11. Handelman GJ, Rosales LM, Barbato D, Luscher J, Adhikarla R, Nicolosi RJ, Finkelstein FO, Ronco C, Kaysen GA, Hoenich NA, Levin NW: Breath ethane in dialysis patients and control subjects. Free Radic Biol Med 35:17-23, 2003
12. Weiss MF, Erhard P, Kader-Attia FA, Wu YC, Deoreo PB, Araki A, Glomb MA, Monnier VM: Mechanisms for the formation of glycoxidation products in end-stage renal disease. Kidney Int 57:2571-2585, 2000
13. Himmelfarb J, McMenamin E, Loseto G, Heinecke JW: Elevated plasma protein 3-chlorotyrosine (3-CT) in chronic hemodialysis patients - a marker of myeloperoxidase (MPO) catalyzed oxidant stress. J Am Soc Nephrol 10:A1430, 1999
14. Ferraro B, Galli F, Frei B, Kingdon E, Canestrari F, Rice-Evans C, Buoncristiani U, Davenport A, Moore KP: Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int 63:2207-2213, 2003
15. Iseki K, Tozawa M, Yoshi S, Fukiyama K: Serum C-reactive protein (CRP) and risk of death in chronic dialysis patients. Nephrol Dial Transplant 14:1956-1960, 1999
16. Yeun JY, Levine RA, Mantadilok V, Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am J Kid Dis 35:469-476, 2000
17. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658, 1999
18. Bayes B, Pastor MC, Bonal J, Junca J, Hernandez JM, Riutort N, Foraster A, Romero R: Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant 18:106-112, 2003
19. Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 9:2368-2376, 1998
20. Yeun JY, Kaysen GA: Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 32:S118-S125, 1998
21. Iseki K, Kawazoe N, Fukiyama K: Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int 44:115-119, 1993
22. Owen WFJ, Lew NL, Liu Y, Lowrie EG, Lazarus JM: The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med 329:1001-1006, 1993
23. Wanner C, Zimmermann J, Quaschning T, Galle J: Inflammation, dyslipidemia and vascular risk factors in hemodialysis patients. Kidney Int Suppl 62:S53-S55, 1997
24. Lowrie EG: Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 32:S105-S112, 1998
25. Stenvinkel P, Alvestrand A: Inflammation in end-stage renal disease: sources, consequences, and therapy. Semin Dial 15:9329-9337, 2002
26. Himmelfarb J, McMenamin ME, Loseto G, Heinecke JW. Myeloperoxidase- catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med 31:1163-1169, 2001
27. Kan E, Undeger U, Bali M, Basaran N: Assessment of DNA strand breakage by the alkaline COMET assay in dialysis patients and the role of vitamin E supplementation. Mutat Res 520:151-159, 2002
28. Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A, Knecht A, Weissgarten Y, Brunner D, Fainaru M, Green MS: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 356:1213-1218, 2000
29. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W: The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial. Circulation 107:992-995, 2003
30. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C: Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol Dial Transplant 10:44-47, 1995
31. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC: Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int 55:2477-2486, 1999
32. Keven K, Kutlay S, Nergizoglu G, Erturk S: Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am J Kidney Dis 41:1233-1239, 2003
33. Cristol JP, Bosc JY, Badiou S, Leblanc M, Lorrho R, Descomps B, Canaud B: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 12:2312-2317, 1997
34. Kobayashi S, Moriya H, Aso K, Ohtake T: Vitamin E-bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells. Kidney Int 63:1881-1887, 2003
35. Amann K, Tornig J, Buzello M, Kuhlmann A, Gross ML, Adamczak M, Ritz E: Effect of antioxidant therapy with dl-alpha-tocopherol on cardiovascular structure in experimental renal failure. Kidney Int 62:877-884, 2002
36. Bonomini M, Forster S, De Risio F, Rychly J, Nebe B, Manfrini V, Klinkmann H, Albertazzi A: Effects of selenium supplementation on immune parameters in chronic uraemic patients on haemodialysis. Nephrol Dial Transplant 10:1654-1661, 1995
37. Chao JC-J, Yuan M-D, Chen P-Y, Chien S-W: Vitamin C and E supplements improve the impaired antioxidant status of and decrease plasma lipid peroxides in hemodialysis patients. J Nutr Biochem 13:653-663, 2002
38. Scott B, Deman A, Peeters P, Van Den Branden C, Stolear JC, Van Camp G, Verbeelen D: Cardiac troponin T and malondialdehyde modified plasma lipids in haemodialysis patients. Nephrol Dial Transplant 18:737-742, 2003
39. Schwedler SB, Metzger T, Schinzel R, Wanner C: Advanced glycation end products and mortality in hemodialysis patients. Kidney Int 62:301-310, 2002
40. Amann K, Ritz C, Adamczak M, Ritz E: Why is coronary heart disease of uraemic patients so frequent and so devastating? Nephrol Dial Transplant 18:631-640, 2003
41. Ziouzenkova O, Asatryan L, Akmal M, Tetta C, Wratten M, Loseto-Wich G, Jurgens G, Heinecke JW, Sevanian A: Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J Biol Chem 274:18916-18924, 1999
42. Van Tits L, De Graaf J, Hak-Lemmers H, Bredie S, Demacker P, Holvoet P, Stalenhoef A: Increased levels of low-density lipoprotein oxidation in patients with familial hypercholesterolemia and in end-stage renal disease patients on hemodialysis. Lab Invest 83:13-21, 2003
43. Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G: Autoantibodies against oxidatively-modified LDL in uremic patients undergoing dialysis. Kidney Int 46:869-876, 1994
44. O'Byrne D, Devaraj S, Islam KN, Collazo R, McDonald L, Grundy S, Jialal I: Low-density lipoprotein (LDL)-induced monocyte-endothelial cell adhesion, soluble cell adhesion molecules, and autoantibodies to oxidized-LDL in chronic renal failure patients on dialysis therapy. Metabolism 50:207-215, 2001
45. MRC: MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:23-33, 2002
46. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 97:425-428, 1998
47. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G:. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
48. Collins R, Peto R, Armitage J: The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 56:53-56, 2002
49. Libby P: Inflammation in atherosclerosis. Nature 420:868-874, 2002